Guard therapeutics

See the webcast.

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. Financial Times Close.

Guard therapeutics

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC The company's Chief Medical Officer, Dr. CEO Tobias Agervald then presented new advancements in the company's preclinical development platform, the so-called GTX platform, aimed at developing new peptides short protein fragments based on the endogenous protein alphamicroglobulin. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. Additional concept validation studies have also been conducted with up to 28 days of treatment in two models of chronic kidney disease, including diabetes-induced kidney disease and focal segmental glomerulosclerosis FSGS. With these results, the company sees promising opportunities to strengthen and expand its position in several new potential therapy areas, including chronic kidney disease. For further information, please contact:. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Attachments: Guard Therapeutics presented development strategy and new preclinical results at RD Update.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. Financial calender Financial reports Share information Corporate governance General meetings, guard therapeutics. Latest Press Releases.

.

Guard Therapeutics is a Swedish biotechnology company that develops novel therapies for diseases with a great medical need for more effective treatments. Our key therapeutic area is nephrology with a focus on acute kidney injuries. Our company is driven by a small team of world-leading scientific, medical and drug development expertise within nephrology. RMC is our most advanced investigational drug which is being developed as a kidney protective treatment in patients undergoing open heart surgery. It is currently in Phase 2 clinical development with a global Phase 2 study running both in Europe and North America. This is also an important seal of quality given the rigorous assessment conducted by the FDA within the framework of an IND application. Guard Therapeutics has also been granted Fast Track designation by the FDA for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Consequently, treatment with RMC has the potential to save lives and prevent other severe consequences of acute kidney injury such loss of kidney function and need for renal replacement therapy. Guard Therapeutics has a proprietary platform of additional research molecules which are currently being evaluated for further preclinical development for kidney diseases. In our clinical trials programme we currently have two ongoing studies.

Guard therapeutics

In line with previous communication patient recruitment was prematurely stopped, and as expected the primary short-term endpoint, incidence of acute kidney injury AKI within 72 hours after surgery, was not reached. Importantly though, pre-defined secondary endpoints demonstrated the intended long-term benefit of RMC with improved kidney function compared to placebo. These results clearly support advancement in the clinical development program and highlight the potential of RMC as a novel short-term treatment for kidney protection. With these results we are back on track, strengthened in our confidence to establish a new and unique treatment for the prevention of kidney injuries in heart surgery and proceed with the clinical development of RMC as planned.

Visualskins

English Swedish. Show more Personal Finance link Personal Finance. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC Speqta AB publ. Show more Markets link Markets. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Click or tap a row for details. Read more. Search the FT Search. Guard Therapeutics announced that the U. A recording of the presentation is available on the company's website. Institutional shareholders Top holders Movers. For further information, please contact:. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented.

TradeDoubler AB. English Swedish. Full study results are expected to be available in the first half of HomeMaid AB publ. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC Price SEK Use our equities screener to discover other potential opportunities. Show more Tech link Tech. All markets data located on FT. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. Show more World link World. Any information that you receive via FT.